A
RAPT

AlphaQuest’s RAPT Therapeutics RAPT Stock Holding History

AlphaQuest’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$10 – 1953
2024
Q3 		$10 Hold
1
– – ﹤0.01% 1858
2024
Q2 		$15 Sell
1
-1,390
-100% -$64.2K ﹤0.01% 1533
2024
Q1 		$99.9K Buy
+1,391
New +$193K 0.02% 818

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AlphaQuest's RAPT Position: Q4 2024 in Review

AlphaQuest sold out of RAPT Therapeutics (RAPT) in Q4 2024, closing a stake of 1 share — an estimated $10 sold.

AlphaQuest first reported a position in RAPT in Q1 2024 and held it in 3 quarters. The position peaked at $99.9K in Q1 2024. 91 funds tracked by Wall St. Rank hold RAPT as of Q4 2024.

  • AlphaQuest reported no remaining RAPT Therapeutics position as of Q4 2024 after selling out during the quarter.
  • AlphaQuest sold 1 RAPT Therapeutics share in Q4 2024, an estimated $10.
  • AlphaQuest first reported a position in RAPT Therapeutics in Q1 2024 and held it in 3 quarters.
  • AlphaQuest's RAPT Therapeutics position peaked at $99.9K in Q1 2024.
  • 91 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2024.

Based on AlphaQuest's 13F filing for Q4 2024, filed 7 Feb 2025.